| Home : Data From Phase 3 Trial Evaluating Fixed-Dose Subcutaneous Combination Of Perjeta® And Herceptin® Using Halozyme's ENHANZE® Drug Delivery Technology To Be Presented At San Antonio Breast Cancer Symposium |
|
Dec 12
2019 |
Data From Phase 3 Trial Evaluating Fixed-Dose Subcutaneous Combination Of Perjeta® And Herceptin® Using Halozyme's ENHANZE® Drug Delivery Technology To Be Presented At San Antonio Breast Cancer Symposium |
|
SAN DIEGO, Dec. 12, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that new data from the global phase III FeDeriCa study conducted by Genentech, a member of the Roche Group, will be presented today at the 2019 San Antonio Breast Cancer Symposium (SABCS).... |
|
|
|
| Source:https://www.prnewswire.com:443/news-releases/data-from-phase-3-trial-evaluating-fixed-dose-subcutaneous-combination-of-perjeta-and-herceptin-using-halozymes-enhanze-drug-delivery-technology-to-be-presented-at-san-antonio-breast-cancer-symposium-300973669. |
| |
|
Related News
|
» Moberg Pharma Comments on the Results of the North American Phase 3 Study With MOB-015
» Alfred Landecker Foundation Pledges 5 Million Euros To The Claims Conference To Support Holocaust Survivors
|
